MENU

RSLS Stock ReShape Lifesciences (RSLS, $5) price may drop as it broke higher Bollinger Band on Jan 13, 2025

A.I.dvisor
at Tickeron.com
Loading...
RSLS - ReShape Lifesciences Inc
Bollinger signal
Bearish Trend
Odds of DOWN Trend
Tickeron
Bollinger signal
Price: $5
Daily change: +$0.5 (+11.11%)
Daily volume: 99.1K
Capitalization: $3.6M
Industry: Medical Specialties
This price move could be a signal that RSLS may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options. A.I.dvisor backtested 32 similar cases where RSLS's price broke its higher Bollinger Band, and of them led to a successful outcome. Odds of Success:

RSLS in -1.98% downward trend, declining for three consecutive days on December 31, 2024

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where RSLS declined for three days, in of 384 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

RSLS broke above its upper Bollinger Band on January 13, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RSLS's RSI Indicator exited the oversold zone, of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 73 cases where RSLS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on January 03, 2025. You may want to consider a long position or call options on RSLS as a result. In of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for RSLS just turned positive on December 27, 2024. Looking at past instances where RSLS's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RSLS advanced for three days, in of 178 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.264) is normal, around the industry mean (23.475). P/E Ratio (0.000) is within average values for comparable stocks, (83.627). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.038) is also within normal values, averaging (41.274).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. RSLS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RSLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.

View a ticker or compare two or three
RSLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of medical devices for the treatment of obesity

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
1001 Calle Amanecer
Phone
+1 949 429-6680
Employees
40
Web
https://www.reshapelifesciences.com